News & Events

News, industry insights and noteworthy events.

At Tanner, we take pride in the success of our partnerships and acknowledge the milestones achieved in pursuing our mission; to improve lives by increasing access to medicines around the world.

For media or press inquiries, please email us.

Contact Us

All Articles

  1. Again Life Italia Announces Partnership with Tanner Pharma Group

    CHARLOTTE, N.C., May 27, 2021 — Again Life Italia S.r.l. (“ALI”), a pharmaceutical biotechnology company headquartered in Italy, and TannerLAC UK Limited (“TannerLAC”), a wholly owned subsidiary of Tanner Pharma Group and company leader in the Latin American market, announced today the signing of a business partnership agreement for Latin America.  With a presence in…

    Read More
  2. Epimune and Tanner Pharma Group enter into Distribution Partnership for Latin America

    Berlin, 27 January 2021 – Epimune GmbH, a molecular diagnostic company that develops, manufactures and commercializes in-vitro diagnostic tests for immune cell quantification from a drop of blood, announced today that it has entered into a license agreement with TannerLAC UK Limited (“TannerLAC”), a wholly owned subsidiary of Tanner Pharma Group for the i.Mune TBNK in-vitro…

    Read More
  3. Elevar Therapeutics and Tanner Pharma Group Announce Launch of Global Named Patient Program to Provide Access to Apealea® (paclitaxel micellar)

    SALT LAKE CITY and CHARLOTTE, N.C., Dec. 1, 2020 /PRNewswire/ — Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, and Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, announced today that they have launched a global…

    Read More
  4. Sending Wilson home: A story of perseverance and teamwork

    (Repost from ZNM) Wilson – a small child with a rare muscle condition called centronuclear myopathy – gets life-saving medical equipment and goes home to his family after spending almost 2 years at the hospital thanks to the support of two patient organizations in Europe and US and the financial assistance and guidance from Tanner…

    Read More
  5. 5 Things to Consider About Commercializing a New Drug in Latin America

    Some of the over 8,000 drugs in development are poised to be breakthrough treatments that will substantially improve or save patients’ lives. The pharmaceutical companies developing these revolutionary medications have at least two goals: ensuring their research investment is profitable and making sure the drug is available to help any person who needs it.   If your company is developing a new drug, you may be ready to achieve these goals in your existing or developed markets, but what about new ones, like Latin America and other emerging markets? If you haven’t done it before, that’s an entirely…

    Read More
  6. The Value of Real-World Data from Global Expanded Access Programs for Rare Diseases

    John Lagus, Tanner’s EVP of Business Development focusing on managed access programs, recently spoke at MarketandMarkets’ Digital Event on Orphan Drugs and Rare Diseases about the value of real-world data (RWD) from expanded access programs (EAPs) for rare diseases. Here are a few highlights from his talk.  Years ago, while in Botswana, John Lagus met a woman who offered her life savings to purchase critical medicine for her daughter. This conversation stayed with…

    Read More
  7. 3 Insights for Effective Comparator Sourcing

    Whether you’re a global pharma or a biotech start-up, every clinical trial will entail overcoming challenges with sourcing, packaging, and the logistics of clinical materials. Choosing the right partner provides you with flexibility and risk mitigation, ensuring you can choose the most cost-effective solution, and avoid delays. Here are some of the key factors to…

    Read More
  8. Tanner Pharma Group and Dompé Initiate Distribution Partnership for Oxervate®

    Tanner Pharma Group and Dompé Initiate Distribution Partnership for Oxervate®   MILAN, ITALY and CHARLOTTE, USA – Dompé farmaceutici S.p.A. (“Dompé”) and Tanner Pharma Group, Inc. today announced they have entered into an agreement whereby Tanner Pharma Group will become Dompé’s exclusive distribution partner for Oxervate (cenegermin) in selected countries. The agreement names Tanner Pharma…

    Read More
  9. Elevar Therapeutics and Tanner Pharma Group Announce Global Named Patient Program to Provide Access to Apealea® (micellular paclitaxel)

    SALT LAKE CITY and CHARLOTTE, N.C., July 27, 2020 /PRNewswire/ — Elevar Therapeutics, Inc. (“Elevar”), a late-stage biopharmaceutical company focused on developing and commercializing promising therapies to address unmet needs in cancer, and Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, today announced a partnership that will facilitate access to Apealea® (micellular paclitaxel) on a named…

    Read More
  10. Tanner Pharma Group Signs Versacloz Distribution Agreement with Tasman Pharma Inc.

    Tanner Pharma Group Signs Versacloz Distribution Agreement with Tasman Pharma Inc. May 12, 2020 For Immediate Release Contact: Telephone: 704-552-8407 Email: versacloz@tannerpharma.com   CHARLOTTE, N.C. – Tanner Pharma Group, a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Tasman Pharma Inc. The agreement names Tanner as a…

    Read More
  11. Increasing Access for Rare Disease Patients Globally

    Patients who suffer from rare diseases often lack access to innovative treatment options because the manufacturer of the medicine cannot justify the investment in registering and commercializing the medicine in countries where patient populations are low.  Managed Access Programs provide  manufacturers of innovative medicines for rare diseases a cost-effective option to provide patients access in countries where the medicine is not commercially available.  If a physician chooses to prescribe such…

    Read More
  12. Tanner Pharma Group and Lawley Pharmaceuticals Initiate Global Named Patient Program for AndroFeme® 1

    PERTH, Australia & CHARLOTTE, N.C., June 15, 2020 –-(BUSINESS WIRE)–Lawley Pharmaceuticals and Tanner Pharma Group announced today that they have initiated a global named patient program for AndroFeme® 1 testosterone cream for women. “Partnering with Tanner gives women access to a female specific testosterone treatment for HSDD which is experienced by one in every three…

    Read More
  13. Tanner Pharma Group Initiates Named Patient Program for XIAFLEX®

    Tanner Pharma Group Initiates Named Patient Program for XIAFLEX® March 2, 2020 08:00 AM Eastern Daylight Time CHARLOTTE, NC –Tanner Pharma Group, Inc. today announced they have partnered with Endo Pharmaceuticals, Inc. to initiate a multi-year Named Patient Program for XIAFLEX® (collagenase clostridium histolyticum), an important nonsurgical treatment option for patients with Dupuytren’s contracture and…

    Read More
  14. Tanner Pharma Group to Attend CTS Europe, DCAT, PharmagoraPlus, PQMD, and GCSG US Conferences

    For Immediate Release Contact: Lindsey Stevens Tanner Pharma Group 704-552-8407 lstevens@tannerpharma.com CHARLOTTE, N.C. – Key directors from Tanner Pharma Group (“Tanner Pharma”), a Charlotte-based global pharmaceutical services company, will attend several international healthcare conferences throughout the upcoming months of March and April. The team will join other global executives for the following events:  Clinical…

    Read More
  15. PQMD Welcomes Tanner Pharma Group to Membership

    For Immediate Release Contact: Lindsey Stevens Tanner Pharma Group 704-552-8407 lstevens@tannerpharma.com Annapolis, Md. – January 23, 2019 – The Partnership for Quality Medical Donations (PQMD), is proud to announce the addition of Tanner Pharma Group to their membership. The Charlotte, N.C., based global pharmaceutical company becomes the 42nd member of PQMD. “Tanner Pharma Group is proud…

    Read More
  16. Tanner Pharma Group Signs Distribution Agreement with Nephcentric LLC

    For Immediate Release Contact: Lindsey Stevens Tanner Pharma Group 704-552-8407 lstevens@tannerpharma.com CHARLOTTE, N.C. – Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Nephcentric LLC (“Nephcentric”), a developer and marketer of evidence based therapeutic options for people with kidney disease and metabolic disorders.…

    Read More
  17. Tanner Pharma Group Signs Distribution Agreement with MannKind Corporation

    For Immediate Release Contact: Lindsey Stevens Tanner Pharma Group 704-552-8407 lstevens@tannerpharma.com CHARLOTTE, N.C. – Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with MannKind Corporation (“MannKind”, NASDAQ: MNKD), a biopharmaceutical company focused on inhaled therapeutic products for patients with diseases such as diabetes…

    Read More
  18. Tanner Pharma Group Delivers on “Last Mile” in Global Health

    For Immediate Release Contact: Lindsey Stevens Tanner Pharma Group 704-552-8407 lstevens@tannerpharma.com SEATTLE, WA – The Max Foundation (“Max”), an international health organization dedicated to serving cancer patients, and Tanner Pharma Group (“Tanner”), a global pharma services company specializing in access to critical medication, are committed partners in bringing thousands of patients around the globe daily…

    Read More

Tanner Pharma Group uses cookies on its website. By continuing to access this website you are agreeing to Tanner Pharma Group’s Data Privacy Policy. For more information, click here.